Indication · Neurology & Neurosurgery
Alzheimer's disease and dementia
Last checked: Nov 21, 2026Source: FDA, ClinicalTrials.gov
Devices
12
Cleared or approved since 2000
PMA and De Novo
4
Higher-risk or first-of-kind devices
Breakthrough devices
5
Authorized through June 30, 2026
Recruiting device trials
180
917 device trials in all
Breakthrough-designated devices
- Elecsys Phospho-Tau (217P) PlasmaRoche Diagnostics · 2026
4 more devices with a free account
Devices
0 devices via PMA. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
No devices on this pathway.
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
IRCCS Centro San Giovanni di Dio FatebenefratelliAcademic, hospital or other
NCT05730023 · 70 participants · Start Feb 1, 2023 · Primary completion Jan 13, 2026
Device: Active tDCS; Placebo tDCS · For: Primary Progressive Aphasia
Sites: Brescia, Italy; Pavia, Italy; Milan, Italy · 4 sites in all
916 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
Research
- Device studies on Alzheimer disease across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.